866-997-4948(US-Canada Toll Free)

Global Alzheimers Disease Drug Market Research Report 2017

Published By :

QYResearch

Published Date : Mar 2017

Category :

Pharmaceutical

No. of Pages : 120 Pages

This report studies the Alzheimers Disease Drug market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, and splits the Alzheimers Disease Drug market by product type and applications/end industries.

In the last several years, global market of alzheimers disease drug change huge. In 2016, global revenue of alzheimers disease drug is nearly 3161.3 M USD. And the global growth rate is at -10.95% from 2012 to 2016


The major players in global Alzheimers Disease Drug market include
Allergan
Eisai
Novartis
Daiichi Sankyo
Merz Pharma
Pfizer
Johnson & Johnson
Lundbeck.

Geographically, this report is segmented into several key Regions, with Sales, Sales, revenue, Market Share (%) and Growth Rate (%) of Alzheimers Disease Drug in these regions, from 2012 to 2022 (forecast), covering
North America
Europe
China
Japan
Row


On the basis of product, the Alzheimers Disease Drug market is primarily split into
Donepezil
Memantine
Rivastigmine


On the basis on the end users/applications, this report covers
Early to Moderate Stages
Moderate to Severe Stages




Table of Contents

1 Alzheimers Disease Drug Market Overview1
1.1 Alzheimers Disease Drug Product Overview1
1.2 Alzheimers Disease Drug Segment by Types (Brand)2
1.2.1 Alzheimers Disease Drug Segment by Types2
1.2.2 Global Alzheimers Disease Drug Sales Market Share (%) by Types in 20163
1.2.3 Donepezil3
1.2.4 Memantine4
1.2.5 Rivastigmine5
1.3 Global Alzheimers Disease Drug Segment by Applications5
1.4 Global Alzheimers Disease Drug Market by Regions (2012-2022)7
1.4.1 North America Alzheimers Disease Drug Status and Prospect (2012-2022)7
1.4.2 China Alzheimers Disease Drug Status and Prospect (2012-2022)8
1.4.3 Europe Alzheimers Disease Drug Status and Prospect (2012-2022)9
1.4.4 Japan Alzheimers Disease Drug Status and Prospect (2012-2022)10
1.5 Global Alzheimers Disease Drug Market Size (2012-2022)11
1.5.1 Global Alzheimers Disease Drug Revenue (M USD) Status and Outlook (2012-2022)11
1.5.2 Global Alzheimers Disease Drug Sales (M Units) Status and Outlook (2012-2022)12
2 Global Alzheimers Disease Drug Market Competition by Manufacturers/Brand14
2.1 Global Alzheimers Disease Drug Sales (M Units) and Share by Manufacturers (2012-2017)14
2.2 Global Alzheimers Disease Drug Revenue (M USD) and Share by Manufacturers (2012-2017)16
2.3 Global Alzheimers Disease Drug Average Price (USD/Unit) by Manufacturers (2012-2017)18
2.4 Manufacturers Alzheimers Disease Drug Headquarters, Found Date, Product Types19
2.5 Alzheimers Disease Drug Market Competitive Situation and Trends21
2.5.1 Alzheimers Disease Drug Market Concentration Rate21
2.5.2 Alzheimers Disease Drug Market Share (%) of Top 3 and Top 5 Manufacturers22
2.5.3 Mergers & Acquisitions, Expansion23
3 Global Alzheimers Disease Drug Sales (M Units), Revenue (M USD) by Regions (2012-2017)27
3.2 Global Alzheimers Disease Drug Sales (M Units) and Market Share (%) by Regions (2012-2017)27
3.3 Global Alzheimers Disease Drug Revenue (M USD) and Market Share (%) by Regions (2012-2017)29
3.3 Global Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)31
3.5 North America Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)31
3.6 Europe Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)32
3.7 China Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)32
3.8 Japan Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2012-2017)33
4 Global Alzheimers Disease Drug Sales, Revenue, Price Trend by Types34
4.1 Global Alzheimers Disease Drug Sales (M Units) and Market Share (%) by Types (2012-2017)34
4.2 Global Alzheimers Disease Drug Revenue and Market Share (%) by Types (2012-2017)36
4.3 Global Alzheimers Disease Drug Price (USD/Unit) by Type (2012-2017)37
4.4 Global Alzheimers Disease Drug Sales Growth by Type (2012-2017)38
5 Global Alzheimers Disease Drug Market Analysis by Applications39
5.1 Global Alzheimers Disease Drug Sales (M Units) and Market Share (%) by Applications (2012-2017)39
5.2 Global Alzheimers Disease Drug Sales Growth Rate (%) by Applications (2012-2017)41
6 Analysis of Alzheimers Disease Drug Industry Key Manufacturers42
6.1 Allergan42
6.1.1 Company Profile42
6.1.2 Product Information43
6.1.3 Sales, Price, Cost, Gross, and Revenue44
6.2 Eisai44
6.2.1 Company Profile44
6.2.2 Product Information45
6.2.3 Sales, Price, Cost, Gross, and Revenue46
6.3 Novartis46
6.3.1 Company Profile46
6.3.2 Product Information47
6.3.3 Sales, Price, Cost, Gross, and Revenue48
6.4 Daiichi Sankyo48
6.4.1 Company Profile48
6.4.2 Product Information49
6.4.3 Sales, Price, Cost, Gross, and Revenue50
6.5 Merz Pharma50
6.5.1 Company Profile50
6.5.2 Product Information51
6.5.3 Sales, Price, Cost, Gross, and Revenue52
6.6 Pfizer52
6.6.1 Company Profile52
6.6.2 Product Information53
6.6.3 Sales, Price, Cost, Gross, and Revenue54
6.7 Johnson & Johnson54
6.7.1 Company Profile54
6.7.2 Product Information55
6.7.3 Sales, Price, Cost, Gross, and Revenue56
6.8 Lundbeck56
6.8.1 Company Profile56
6.8.2 Product Information57
6.8.3 Sales, Price, Cost, Gross, and Revenue58
7 Alzheimers Disease Drug Manufacturing Cost Analysis59
7.1 Alzheimers Disease Drug R&D Cost Analysis59
7.1.1Clinical Phase Costs60
7.1.2 Capitalized Costs61
7.2 Proportion of Manufacturing Cost Structure62
7.2.1 Raw Materials62
7.2.2 Labor Cost63
7.2.3 Manufacturing Expenses68
7.3 Manufacturing Process Analysis of Alzheimers Disease Drug69
8 Industrial Chain, Sourcing Strategy and Downstream Buyers70
8.1 Alzheimers Disease Drug Industrial Chain Analysis70
8.2 Upstream Raw Materials Sourcing71
8.4 Downstream Buyers71
9 Marketing Strategy Analysis, Distributors/Traders73
9.1 Marketing Channel73
9.2 Market Positioning74
9.2.1 Market Positioning74
9.2.2 Brand Strategy75
9.2.2.1 Introducing pharmaceutical branding strategies75
9.2.2.2 Building pharmaceutical brands76
9.2.2.3 Communicating pharmaceutical brands76
9.2.2.4 Alternative brand models77
9.2.2.5 The future of pharmaceutical branding77
9.3 Distributors/Traders List78
10 Alzheimers drug-development pipeline79
10.1 Phase III80
10.2 Phase II83
10.3 Phase I88
10.4 Biomarkers91
11 Global Alzheimers Disease Drug Market Forecast (2017-2022)92
11.1 Global Alzheimers Disease Drug Sales (M Units), Revenue (M USD) Forecast (2017-2022)92
11.1.1 Global Alzheimers Disease Drug Sales (M Units) and Growth Rate (%) Forecast (2017-2022)92
11.1.2 Global Alzheimers Disease Drug Revenue (M USD) and Growth Rate (%) Forecast (2017-2022)93
11.1.3 Global Alzheimers Disease Drug Price and Trend Forecast (2017-2022)94
11.2 Global Alzheimers Disease Drug Sales (M Units) and Revenue (M USD) Forecast by Regions (2017-2022)94
11.2.1 North America Alzheimers Disease Drug Sales (M Units) and Revenue (M USD) Forecast (2017-2022)95
11.2.2 Europe Alzheimers Disease Drug Sales (M Units) and Revenue (M USD) Forecast (2017-2022)97
11.2.3 China Alzheimers Disease Drug Sales (M Units) and Revenue (M USD) Forecast (2017-2022)99
11.2.4 Japan Alzheimers Disease Drug Sales (M Units) and Revenue (M USD) Forecast (2017-2022)101
11.3 Global Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) Forecast by Type (2017-2022)102
11.4 Global Alzheimers Disease Drug Sales (M Units) Forecast by Application (2017-2022)103
12 Research Findings and Conclusion104
13 Methodology and Data Source105
13.1 Methodology/Research Approach105
13.1.1 Research Programs/Design105
13.1.2 Market Size Estimation106
13.1.3 Market Breakdown and Data Triangulation107
13.2 Data Source108
13.2.1 Secondary Sources108
13.2.2 Primary Sources109
13.3 Disclaimer110
13.4 Author List111


List of Table

List of Tables and Figures

Figure Product Picture of Alzheimers Disease Drug1
Table Alzheimers Disease Drug Segment by Types2
Figure Global Alzheimers Disease Drug Sales Market Share (%) by Types in 20163
Figure Product Picture of Donepezil4
Figure Product Picture of Memantine4
Figure Product Picture of Rivastigmine5
Table Global Alzheimers Disease Drug Segment by Applications5
Table Treatments at a Glance6
Figure North America Alzheimers Disease Drug Revenue (M USD) and Growth Rate (%) (2012-2022)7
Figure China Alzheimers Disease Drug Revenue (M USD) and Growth Rate (%) (2012-2022)8
Figure Europe Alzheimers Disease Drug Revenue (M USD) and Growth Rate (%) (2012-2022)9
Figure Japan Alzheimers Disease Drug Revenue (M USD) and Growth Rate (%) (2012-2022)10
Figure Global Alzheimers Disease Drug Revenue (M USD) Status and Outlook (2012-2022)11
Figure Global Alzheimers Disease Drug Sales (M Units) Status and Outlook (2012-2022)12
Figure Global Alzheimers Disease Drug Sales Market Share (%) by Applications in 201613
Table Global Alzheimers Disease Drug Sales (M Units) of Key Manufacturers (2012-2017)14
Figure 2016 Alzheimers Disease Drug Sales Share (%) by Manufacturers15
Figure 2017 Alzheimers Disease Drug Sales Share (%) by Manufacturers16
Table Global Alzheimers Disease Drug Revenue (M USD) by Manufacturers (2012-2017)16
Table 2016 Global Alzheimers Disease Drug Revenue Share (%) by Manufacturers17
Table 2017 Global Alzheimers Disease Drug Revenue Share (%) by Manufacturers18
Table Global Market Alzheimers Disease Drug Average Price (USD/Unit) of Key Manufacturers (2012-2017)18
Figure Global Market Alzheimers Disease Drug Average Price (USD/Unit) of Key Manufacturers in 201619
Table Manufacturers Alzheimers Disease Drug Headquarters and Found Date19
Table Manufacturers Alzheimers Disease Drug Brand20
Table 2016 Global Alzheimers Disease Drug Revenue Share (%) by Manufacturers21
Figure Alzheimers Disease Drug Market Share (%) of Top 3 Manufacturers22
Figure Alzheimers Disease Drug Market Share (%) of Top 5 Manufacturers23
Table Mergers & Acquisitions, Expansion23
Table Global Alzheimers Disease Drug Sales (M Units) by Regions (2012-2017)27
Table Global Alzheimers Disease Drug Sales Market Share by Regions (2012-2017)27
Figure 2016 Global Alzheimers Disease Drug Sales Market Share (%) by Regions28
Figure 2017 Global Alzheimers Disease Drug Sales Market Share (%) by Regions28
Table Global Alzheimers Disease Drug Revenue (M USD) by Regions (2012-2017)29
Table Global Alzheimers Disease Drug Revenue Market Share (%) by Regions (2012-2017)29
Figure 2016 Global Alzheimers Disease Drug Revenue Market Share (%) by Regions30
Figure 2017 Global Alzheimers Disease Drug Revenue Market Share (%) by Regions30
Table Global Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)31
Table North America Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)31
Table Europe Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)32
Table China Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)32
Table Japan Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)33
Table Global Alzheimers Disease Drug Sales (M Units) by Types (2012-2017)34
Table Global Alzheimers Disease Drug Sales Share (%) by Types (2012-2017)34
Figure 2016 Sales Market Share (%) of Alzheimers Disease Drug by Types35
Figure 2017 Sales Market Share (%) of Alzheimers Disease Drug by Types35
Table Global Alzheimers Disease Drug Revenue (M USD) by Types (2012-2017)36
Table Global Alzheimers Disease Drug Revenue Share (%) by Types (2012-2017)36
Figure 2016 Revenue Market Share (%) of Alzheimers Disease Drug by Types36
Figure 2017 Revenue Market Share (%) of Alzheimers Disease Drug by Types37
Table Global Alzheimers Disease Drug Price (USD/Unit) by Types (2012-2017)37
Figure Global Alzheimers Disease Drug Sales Growth (%) by Type (2012-2017)38
Table Global Alzheimers Disease Drug Sales (M Units) by Applications (2012-2017)39
Table Global Alzheimers Disease Drug Sales Market Share (%) by Applications (2012-2017)39
Figure Global Alzheimers Disease Drug Sales Market Share (%) by Applications in 201640
Figure Global Alzheimers Disease Drug Sales Market Share (%) by Applications in 201740
Figure Global Alzheimers Disease Drug Sales Growth Rate (%) by Applications (2012-2017)41
Table Allergan Company Profile42
Table Alzheimers Disease Drug Product Introduction of Allergan43
Table Alzheimers Disease Drug Ssles (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Allergan 2012-201744
Table Eisai Company Profile44
Table Alzheimers Disease Drug Product Introduction of Eisai45
Table Alzheimers Disease Drug Production (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Eisai 2012-201746
Table Novartis Company Profile46
Table Alzheimers Disease Drug Product Introduction of Novartis47
Table Alzheimers Disease Drug Production (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Novartis 2012-201748
Table Daiichi Sankyo Company Profile48
Table Alzheimers Disease Drug Product Introduction of Daiichi Sankyo49
Table Alzheimers Disease Drug Production (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Daiichi Sankyo 2012-201750
Table Merz Pharma Company Profile50
Table Alzheimers Disease Drug Product Introduction of Merz Pharma51
Table Alzheimers Disease Drug Production (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Merz Pharma 2012-201752
Table Pfizer Company Profile52
Table Alzheimers Disease Drug Product Introduction of Pfizer53
Table Alzheimers Disease Drug Production (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Pfizer 2012-201754
Table Johnson & Johnson Company Profile54
Table Alzheimers Disease Drug Product Introduction of Johnson & Johnson55
Table Alzheimers Disease Drug Production (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Johnson & Johnson 2012-201756
Table Lundbeck Company Profile56
Table Alzheimers Disease Drug Product Introduction of Lundbeck57
Table Alzheimers Disease Drug Production (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Lundbeck 2012-201758
Figure typical phases from research to the market for a drug candidate60
Table Out-of-pocket Preclinical and Clinical Period Cost per Investigational Biopharmaceutical Compound61
Table Capitalized Preclinical and Clinical Period costs per Investigational Biopharmaceutical Compound61
Figure Manufacturing Cost Structure of Alzheimers Disease Drug62
Figure Assessment of API Manufacturing Cost By Region63
Figure 2016 Manufacturing Labor Cost Per Hour in China as a Proportion of Those in Other Countries (%)64
Figure Manufacturing Labor Costs in Select Provinces and Countries in 201664
Figure 2016 Global Manufacturing Competitiveness Index rankings by country65
Figure US Nonfarm Unit Labor Cost 2014-201666
Figure United States Average Hourly Wages (USD/H) 2016-201766
Figure China Labor Cost Index 2014-201667
Figure China Average Yearly Wages 2006-201667
Figure Euro Area Labor Cost 2014-201668
Figure Japan Overview of Average Monthly Wages 2012-2017(JPY Thousand/Month)68
Figure Manufacturing Process Analysis of Alzheimers Disease Drug69
Figure Alzheimers Disease Drug Industrial Chain Analysis70
Table Major Buyers of Alzheimers Disease Drug71
Figure Marketing Channel for Alzheimers Disease73
Figure Alzheimers Disease Marketing Channel74
Table Distributors/Traders List78
Figure Agents currently in clinical trials for AD80
Table Agents currently in phase III of development and their mechanism of action80
Table Agents currently in phase II of AD drug development and their mechanism of action83
Table Agents currently in phase I of development and their mechanism of action88
Table Percent of trials with specific biomarkers included91
Figure Global Alzheimers Disease Drug Sales (M Units) and Growth Rate (%) Forecast (2017-2022)92
Figure Global Alzheimers Disease Drug Revenue (M USD) and Growth Rate (%) Forecast (2017-2022)93
Figure Global Alzheimers Disease Drug Price and Trend Forecast (2017-2022)94
Table Global Alzheimers Disease Drug Sales (M Units) Forecast by Regions (2017-2022)94
Figure North America Alzheimers Disease Drug Sales (M Units) and Growth Rate (%) Forecast (2017-2022)95
Figure North America Alzheimers Disease Drug Revenue and Growth Rate (%) Forecast (2017-2022)96
Figure Europe Alzheimers Disease Drug Sales (M Units) and Growth Rate (%) Forecast (2017-2022)97
Figure Europe Alzheimers Disease Drug Revenue and Growth Rate (%) Forecast (2017-2022)98
Figure China Alzheimers Disease Drug Sales (M Units) and Growth Rate (%) Forecast (2017-2022)99
Figure China Alzheimers Disease Drug Revenue and Growth Rate (%) Forecast (2017-2022)100
Figure Japan Alzheimers Disease Drug Sales (M Units) and Growth Rate (%) Forecast (2017-2022)101
Figure Japan Alzheimers Disease Drug Revenue and Growth Rate (%) Forecast (2017-2022)102
Table Global Alzheimers Disease Drug Sales (M Unit) Forecast by Type (2017-2022)102
Table Global Alzheimers Disease Drug Revenue (M USD) Forecast by Type (2017-2022)103
Table Global Alzheimers Disease Drug Price (USD/Unit) Forecast by Type (2017-2022)103
Table Global Alzheimers Disease Drug Sales (M Units) Forecast by Application (2017-2022)103
Table Research Programs/Design for This Report105
Figure Bottom-up and Top-down Approaches for This Report107
Figure Data Triangulation108
Table Key Data Information from Secondary Sources109
Table Key Data Information from Primary Sources109

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *